Xgeva Slightly Better Than Zometa at Reducing Breast Cancer Bone Complications

Sign in to receive recommendations (Learn more)

In up to 80% of women diagnosed with metastatic breast cancer, the cancer spreads to one or more bones. Bone metastases are painful and can weaken bones. Doctors use the term "skeletal related event" (SRE) when talking about any of these complications related to cancer that has spread to the bones:

  • breaking a bone with metastatic cancer in it (pathologic fracture)
  • needing radiation therapy or surgery to ease bone pain or other complications from the cancer
  • spinal cord compression caused by the vertebrae (back bones) weakening or collapsing

Zometa (chemical name: zoledronic acid) is used to strengthen bones in women diagnosed with metastatic breast cancer that has spread to the bones. Zometa also is used to lower their risk of an SRE. A study found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, was somewhat better than Zometa at lowering the risk of SREs and lengthening the time before an SRE develops.

Denosumab, branded as Prolia, is approved by the U.S. Food and Drug Administration (FDA) to treat postmenopausal women diagnosed with osteoporosis at high risk of breaking a bone or who can't take or haven't gotten any benefits from other osteoporosis treatments. In November 2010, Xgeva was approved by the FDA to reduce the risk of SREs caused by certain cancers that have spread to bone, including breast cancer. FDA approval of Xgeva happened after this study was released.

Targeted therapy medicines target specific aspects of cells that affect how they behave. Some targeted therapies, including denosumab, are antibodies that work like the antibodies made naturally by the body's immune system. Denosumab targets the RANK ligand (RANKL) protein that affects the activity of certain bone cells called osteoclasts. Osteoclasts cause a certain amount of bone breakdown to help regulate the body's calcium level. Osteoclasts tend to be overactive when breast cancer spreads to the bones. Overactive osteoclasts can cause bone pain and bone destruction. By blocking the RANKL protein, denosumab lowers the activity level of the osteoclasts, which reduces the risk of pain and other bone complications. Denosumab doesn't treat the cancer, only the bone complications caused by the cancer.

In this study, 2,046 women diagnosed with metastatic breast cancer that had spread to the bones were split into two groups:

  • about half the women got Xgeva every 4 weeks; Xgeva is given as an injection under the skin
  • the other women got Zometa every 4 weeks; Zometa is given intravenously

To make sure neither the doctors nor the women knew who was getting which medicine, all the women got both an injection and an intravenous infusion, one of which had no medicine in it, every 4 weeks. All the women were advised to take supplemental calcium and vitamin D during the study.

The researchers watched to see if any of the women had bone pain, bone fractures, or spinal cord compression, as well as whether any of the women needed radiation therapy or surgery to treat bone complications.

The risk of developing one or more bone complications was lower in women who got Xgeva compared to women who got Zometa; the risk of developing more than one bone complication was 23% lower in women who got Xgeva.

The length of time before a first bone complication developed was 18% longer and the length of time before a first and later bone complications developed was 23% longer in women who got Xgeva compared to women who got Zometa.

Overall survival and the risk of the cancer progressing were the same with both treatments.

Xgeva seemed to cause the same side effects as Zometa. A rare but serious side effect of both medicines is osteonecrosis of the jaw, a condition in which the cells in the jawbone start to die. Osteonecrosis of the jaw developed in 1% to 2% of the women no matter which medicine they received.

Some doctors think Xgeva may be a good alternative to Zometa because it appears to work a little better and because it's given as an injection under the skin rather than as an intravenous infusion.

If you've been diagnosed with metastatic breast cancer that has spread to one or more bones, you and your doctor will develop a treatment plan to minimize any pain you have and reduce your risk of bone complications. Zometa may be part of your plan. Since the FDA has approved Xgeva, you may want to ask your doctor if Xgeva might be a better alternative for you.

Was this resource helpful?

Yes No
C3a
C3b
Evergreen-donate
Back to Top